AR011189A1 - 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion - Google Patents
1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacionInfo
- Publication number
- AR011189A1 AR011189A1 ARP980101096A ARP980101096A AR011189A1 AR 011189 A1 AR011189 A1 AR 011189A1 AR P980101096 A ARP980101096 A AR P980101096A AR P980101096 A ARP980101096 A AR P980101096A AR 011189 A1 AR011189 A1 AR 011189A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- hydrogen
- 6alkyl
- preparation
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1,4-benzotiazepin-1,1-dioxidos que comprende la formula (I), en la que R1 es un grupo alquilo de C1-6 de cadena lineal; R2 es un grupo alquilo deC1-6 de cadena lineal; R3 es hidrogeno o un grupo OR11 en el que R11 es hidrogeno, un grupoalquilo de C1-6 o alquilcarbonilo de C1-6 opcionalmentesustituidos; R4 es piridilo o fenilo opcionalmente sustituido; R5, R6 y R8 son iguales o diferentes y cada uno se selecciona de hidrogeno, halogeno, ciano,R15-acetiluro, OR15, alquilo de C1-6op cionalmente sustituido, COR15, CH(OH)R15, S(O)nR15, P(O)(OR15)2, OCOR15, OCF3, OCN, SCN, NHCN, CH2OR15, CHO,(CH2)pCN, CONR12R13, (CH2)pCO2R15, (CH2)pNR12R13, CO2R15, NHCOCF3, NHSO2R15, OCH2OR15, OCH=CHR15, O(CH2CH2O)nR15,O(CH2)pSO3R15, O(CH2)pNR12R13 yO(CH2)pN+R12R14 en los que p es un numero entero de 1-4; n es un numero entero de 0-3 y R12, R13, R14 y R15 se seleccionan independientemente de hidrogeno yalquilo de C1-6 opcionalmente sustituido; R7 es un grupo dela formula (II) en la que los grupos hidroxilo pueden estar sustituidos con acetilo o bencilo,o formula:-alquil(C1-C6)-R17 en el que el grupo alquilo puede estar sustituido con uno o más grupos hidroxilo; R16 es -COOH o -CH2-OH; R17 es H, -OH,-NH2,-COOH o COOR1 8; R18 es alquilo (C1-C4) o -NH-alquilo (C1-C4); X es -NH- u -O-; y R9 y R10 son iguales o diferentes y cada uno es hidrogeno o alquilo de C1-6;y sus sales, solvatos y derivados fisiologicamente funcionales; a composicionesfarmacéuticas que los con tienen y a su uso en medicina, particularmente en laprofilaxis y tratamiento de estados hiperlipemiantes, tal como la ateroesclorosis, a sus procedimientos para su preparacion y nuevos compuestosintermediariospara su preparacion.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97104348 | 1997-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR011189A1 true AR011189A1 (es) | 2000-08-02 |
Family
ID=8226598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980101096A AR011189A1 (es) | 1997-03-14 | 1998-03-11 | 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion |
Country Status (23)
Country | Link |
---|---|
US (2) | US6020330A (es) |
EP (1) | EP0864582B1 (es) |
JP (1) | JP3282998B2 (es) |
KR (1) | KR19980080223A (es) |
CN (1) | CN1070484C (es) |
AR (1) | AR011189A1 (es) |
AT (1) | ATE242258T1 (es) |
AU (1) | AU731575B2 (es) |
BR (1) | BR9801126A (es) |
CA (1) | CA2231971C (es) |
CZ (1) | CZ75998A3 (es) |
DE (1) | DE69815180T2 (es) |
DK (1) | DK0864582T3 (es) |
ES (1) | ES2198613T3 (es) |
HU (1) | HUP9800541A3 (es) |
ID (1) | ID20053A (es) |
IL (1) | IL123648A (es) |
NZ (1) | NZ329932A (es) |
PL (1) | PL325363A1 (es) |
PT (1) | PT864582E (es) |
RU (1) | RU2179977C2 (es) |
TR (1) | TR199800444A2 (es) |
ZA (1) | ZA982140B (es) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
US6262277B1 (en) * | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
PT864582E (pt) * | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos |
AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
JP2002533414A (ja) | 1998-12-23 | 2002-10-08 | ジー.ディー.サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ |
US6569905B1 (en) | 1998-12-23 | 2003-05-27 | G.D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
ES2200587T3 (es) | 1998-12-23 | 2004-03-01 | G.D. Searle Llc | Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares. |
WO2000038721A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
EP1140187B1 (en) * | 1998-12-23 | 2003-09-03 | G.D. Searle LLC. | Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications |
EA009466B1 (ru) | 1998-12-23 | 2007-12-28 | Джи.Ди. Сирл Ллс | Ингибитор белка, переносящего эфир холестерила |
DE69907960T2 (de) | 1998-12-23 | 2004-02-26 | G.D. Searle Llc, Chicago | Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen |
DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
GB9914745D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
EP1286984A2 (en) | 2000-03-10 | 2003-03-05 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
WO2001068096A2 (en) * | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
US20020183307A1 (en) * | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
GB0121337D0 (en) * | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
PL216023B1 (pl) | 2001-09-08 | 2014-02-28 | Astrazeneca Ab | Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny |
US6740663B2 (en) * | 2001-11-02 | 2004-05-25 | G.D. Searle, Llc | Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
US6852753B2 (en) | 2002-01-17 | 2005-02-08 | Pharmacia Corporation | Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
GB0201850D0 (en) * | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
CN1930137B (zh) | 2004-02-27 | 2011-07-20 | 旭化成制药株式会社 | 苯并硫氮杂卓和苯并虑平化合物 |
DE102005033099A1 (de) * | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
US9339480B2 (en) * | 2008-11-26 | 2016-05-17 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
MX345040B (es) | 2010-11-08 | 2017-01-16 | Albireo Ab | Una combinacion farmaceutica que comprende un inhibidor de ibat y un aglutinante de acido biliar. |
RS60901B1 (sr) | 2010-11-08 | 2020-11-30 | Albireo Ab | Ibat inhibitori za lečenje oboljenja jetre |
CN104023718B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
CN104023727B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
AU2014228850A1 (en) | 2013-03-15 | 2015-10-29 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CA2977588C (en) * | 2015-03-02 | 2023-10-03 | Apeiron Biologics Ag | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases |
CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP7391048B2 (ja) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3100691A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
FI3921028T3 (fi) | 2019-02-06 | 2023-01-31 | Bentsotiadiatsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina | |
CA3127408A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
JP2022520121A (ja) | 2019-02-12 | 2022-03-28 | ミルム ファーマシューティカルズ インコーポレイテッド | 胆汁うっ滞を治療する方法 |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
TW202134218A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
JP2023504645A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
AU2023255249A1 (en) | 2022-04-22 | 2024-10-17 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
WO2024008766A1 (en) | 2022-07-05 | 2024-01-11 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US20240173333A1 (en) | 2022-11-03 | 2024-05-30 | Albireo Ab | Treating Alagille Syndrome (ALGS) |
US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
HUT71819A (en) * | 1992-11-09 | 1996-02-28 | Boots Co Plc | 1,4-benzothiazepine derivatives and pharmaceutical compositions containing them |
IL108634A0 (en) * | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
IL108633A (en) * | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
PT864582E (pt) * | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos |
-
1998
- 1998-03-03 PT PT98103702T patent/PT864582E/pt unknown
- 1998-03-03 AT AT98103702T patent/ATE242258T1/de active
- 1998-03-03 EP EP98103702A patent/EP0864582B1/en not_active Expired - Lifetime
- 1998-03-03 ES ES98103702T patent/ES2198613T3/es not_active Expired - Lifetime
- 1998-03-03 DK DK98103702T patent/DK0864582T3/da active
- 1998-03-03 DE DE69815180T patent/DE69815180T2/de not_active Expired - Lifetime
- 1998-03-11 AR ARP980101096A patent/AR011189A1/es unknown
- 1998-03-12 IL IL12364898A patent/IL123648A/xx not_active IP Right Cessation
- 1998-03-12 RU RU98104950/04A patent/RU2179977C2/ru not_active IP Right Cessation
- 1998-03-12 ID IDP980360A patent/ID20053A/id unknown
- 1998-03-12 HU HU9800541A patent/HUP9800541A3/hu unknown
- 1998-03-12 TR TR1998/00444A patent/TR199800444A2/xx unknown
- 1998-03-12 CA CA002231971A patent/CA2231971C/en not_active Expired - Fee Related
- 1998-03-12 NZ NZ329932A patent/NZ329932A/xx unknown
- 1998-03-12 CZ CZ98759A patent/CZ75998A3/cs unknown
- 1998-03-12 AU AU58349/98A patent/AU731575B2/en not_active Ceased
- 1998-03-13 CN CN98108046A patent/CN1070484C/zh not_active Expired - Fee Related
- 1998-03-13 KR KR1019980008440A patent/KR19980080223A/ko not_active Application Discontinuation
- 1998-03-13 US US09/041,953 patent/US6020330A/en not_active Expired - Lifetime
- 1998-03-13 BR BR9801126A patent/BR9801126A/pt not_active IP Right Cessation
- 1998-03-13 JP JP06266598A patent/JP3282998B2/ja not_active Expired - Fee Related
- 1998-03-13 ZA ZA982140A patent/ZA982140B/xx unknown
- 1998-03-14 PL PL98325363A patent/PL325363A1/xx not_active Application Discontinuation
-
1999
- 1999-07-27 US US09/361,530 patent/US6114322A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ID20053A (id) | 1998-09-17 |
DK0864582T3 (da) | 2003-09-29 |
AU731575B2 (en) | 2001-04-05 |
CA2231971A1 (en) | 1998-09-14 |
ZA982140B (en) | 1998-09-14 |
HU9800541D0 (en) | 1998-05-28 |
EP0864582B1 (en) | 2003-06-04 |
CN1194979A (zh) | 1998-10-07 |
EP0864582A3 (en) | 1998-10-21 |
RU2179977C2 (ru) | 2002-02-27 |
HUP9800541A1 (hu) | 1999-06-28 |
US6020330A (en) | 2000-02-01 |
BR9801126A (pt) | 2000-03-21 |
CN1070484C (zh) | 2001-09-05 |
IL123648A0 (en) | 1998-10-30 |
AU5834998A (en) | 1998-09-17 |
ATE242258T1 (de) | 2003-06-15 |
PT864582E (pt) | 2003-10-31 |
IL123648A (en) | 2000-11-21 |
HUP9800541A3 (en) | 2000-08-28 |
PL325363A1 (en) | 1998-09-28 |
US6114322A (en) | 2000-09-05 |
JPH10279568A (ja) | 1998-10-20 |
NZ329932A (en) | 1999-01-28 |
TR199800444A3 (tr) | 1998-10-21 |
ES2198613T3 (es) | 2004-02-01 |
DE69815180D1 (de) | 2003-07-10 |
DE69815180T2 (de) | 2004-04-29 |
CA2231971C (en) | 2008-05-20 |
EP0864582A2 (en) | 1998-09-16 |
CZ75998A3 (cs) | 1998-09-16 |
TR199800444A2 (xx) | 1998-10-21 |
KR19980080223A (ko) | 1998-11-25 |
JP3282998B2 (ja) | 2002-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR011189A1 (es) | 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion | |
AR007077A1 (es) | Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento | |
AR018169A1 (es) | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret | |
AR037247A1 (es) | Compuestos inhibidores de dipeptidil peptidasa iv (dp-iv), sus composiciones farmaceuticas y usos, y metodos de tratamiento de enfermedades de humanos tales como tolerancia alterada a la glucosa, diabetes tipo 2 e hiperglucemia | |
AR037504A1 (es) | Derivados de 1,6-naftiridina, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la diabetes y trastornos relacionados | |
AR023659A1 (es) | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos | |
HUP0001192A2 (hu) | Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására | |
AR033594A1 (es) | Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios | |
ES2162466T3 (es) | Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen. | |
AR047008A1 (es) | Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos. | |
AR048717A1 (es) | Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
MX9307654A (es) | Derivados de amina, proceso para su preparacion y composicion farmaceutica que los contiene. | |
AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
ATE356624T1 (de) | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
ES2119326T3 (es) | Compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
IS5401A (is) | Samsetning mónóamínoxídasa hemils og h5-HT1B mótlyfs eða gerandefnis með hlutaverkun | |
CO4810374A1 (es) | Nueva utilizacion de compuestos para actividad anti- pruritica | |
CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
NO812355L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater | |
DK118083D0 (da) | Theophyllinylalkyloxadiazoler eller additionssalte deraf, deres fremstilling og anvendelse som laegemidler | |
ES2116467T3 (es) | Derivados de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona, su preparacion y los medicamentos que les contienen. | |
DK0379412T3 (da) | Derivater af 1,8-benzonaphthyridin, fremstilling af disse forbindelser og midler, som indeholder forbindelserne | |
ES2133686T3 (es) | Nuevos derivados de benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. |